Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Melanoma, Cutaneous Malignant × Paclitaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 501 Carcinoma, Non-Small-Cell Lung 423 Ovarian Neoplasms 283 Lung Neoplasms 174 Neoplasms 134 Fallopian Tube Neoplasms 132 Esophageal Neoplasms 114 Stomach Neoplasms 112 Triple Negative Breast Neoplasms 108 Carcinoma, Ovarian Epithelial 108 Neoplasm Metastasis 105 Squamous Cell Carcinoma of Head and Neck 85 Endometrial Neoplasms 80 Head and Neck Neoplasms 72 Esophageal Squamous Cell Carcinoma 67 Uterine Cervical Neoplasms 63 Recurrence 45 Adenocarcinoma of Lung 40 Urinary Bladder Neoplasms 39 Parkinson Disease 4, Autosomal Dominant Lewy Body 39 Carcinoma 38 Melanoma 35 Adenocarcinoma Of Esophagus 34 Prostatic Neoplasms 32 Carcinoma, Squamous Cell 32 Small Cell Lung Carcinoma 28 Pancreatic Neoplasms 28 Unspecified Adult Solid Tumor, Protocol Specific 26 Breast Neoplasms, Male 26 Colorectal Neoplasms 24

Interventions

pembrolizumab 2 nintedanib 1 dabrafenib 1 Vitamin D 1 Surveys and Questionnaires 1 Paclitaxel 1 Eye Movement Desensitization Reprocessing 1 Electrochemotherapy 1 Cholecalciferol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02308553 2020-10-14

NIPAWILMA

University Hospital, Essen

Phase 1/2 Completed

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡